Perrigo Company PRGO Women's Health — Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Perrigo Company in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Perrigo Company’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Perrigo Company's women's health — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Perrigo Company's women's health — net sales?
- Perrigo Company (PRGO) reported women's health — net sales of $55.1M in Q1 2026.
- How has Perrigo Company's women's health — net sales changed year-over-year?
- Perrigo Company's women's health — net sales increased by 11.3% year-over-year, from $49.5M to $55.1M.
- What is the long-term trend for Perrigo Company's women's health — net sales?
- Over 4 years (2021 to 2025), Perrigo Company's women's health — net sales has grown at a 23.8% compound annual growth rate (CAGR), from $92.7M to $218.1M.
- What does women's health — net sales mean?
- This metric represents the total revenue generated from the sale of products specifically categorized within the Women's Health business segment. It reflects the market demand and commercial performance of the company's specialized portfolio focused on reproductive, hormonal, and related therapeutic health solutions. Tracking this figure allows investors to evaluate the growth trajectory and competitive positioning of the company's dedicated women's health franchise.